08:51 AM EDT, 07/11/2025 (MT Newswires) -- Mira Pharmaceuticals ( MIRA ) said Friday that new preclinical results from obesity and nicotine addiction treatment drug, SKNY-1, showed a "clear reversal" of anxiety-related behavior.

The findings suggest that SKNY-1 may deliver therapeutic effects such as reversing high-calorie food and nicotine cravings without causing emotional or behavioral disruption, the company said.

Looking ahead, Mira said the company is preparing to seek shareholder approval for its proposed acquisition of Skny Pharmaceuticals, and that pending approval, it will begin investigational new drug-enabling studies for SKNY-1.

Shares of the company rose nearly 6% in recent Friday premarket activity.